-
ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC
In the global field of hepatocellular carcinoma (HCC) treatment, the synergistic use of targeted therapy and immunotherapy has led to breakthrough progress, significantly prolonging survival for patients with advanced disease and bringing renewed hope to countless individuals. Yet medical progress never stands still. How to further transcend existing treatment paradigms and unlock deeper survival benefits…
-
ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm
The Barcelona Clinic Liver Cancer (BCLC) staging system is the cornerstone framework guiding treatment decisions for hepatocellular carcinoma (HCC). Its fundamental role lies in stratifying patients according to three key prognostic determinants—tumor burden, liver function, and performance status—thereby aligning prognosis assessment with evidence-based treatment recommendations for each disease stage.
-
ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen
The combination of atezolizumab plus bevacizumab (the “T+A” regimen) has established a new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the lack of long-term survival data and uncertainties regarding its effectiveness in complex real-world populations have remained major clinical concerns.
-
ESMO International Perspective | Global Lung Cancer Experts Discuss the OptiTROP-Lung04 Study: Sacituzumab Tirumotecan Breaks Through Post-TKI Resistance
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) were among the earliest beneficiaries of precision targeted therapy. However, once tyrosine kinase inhibitor (TKI) resistance develops and disease progression occurs, the choice of subsequent therapy has long posed a major challenge for clinicians worldwide. The emergence of innovative treatments such as antibody–drug conjugates (ADCs) has brought…
-
ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer
Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies worldwide. Approximately 60–70% of patients are diagnosed at intermediate or advanced stages, making the pursuit of innovative therapeutic strategies that deliver meaningful survival benefit a long-standing global challenge. Against this backdrop, the TALENTOP study, led by Fan Jia, Academician and Principal Investigator from Zhongshan Hospital, Fudan…
-
ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC
The Phase III BURAN trial, presented at the recent ESMO Congress, evaluated the PI3K inhibitor buparlisib plus paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who had progressed after PD-1/PD-L1 inhibitor therapy. The study failed to demonstrate improvements in progression-free survival (PFS) or overall survival (OS) compared with…
-
ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care
With the rapid evolution of immunotherapy–targeted therapy combinations, the management of advanced hepatocellular carcinoma (HCC) has entered a new era. Yet for patients with traditionally high-risk features—such as macrovascular invasion or extrahepatic spread—clinical outcomes have historically remained poor, posing a persistent therapeutic challenge.
-
[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma
For patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at high postoperative risk, the standard of adjuvant concurrent chemoradiotherapy (CRT) has remained unchanged since 2004—despite persistent rates of recurrence and metastasis. Recently, the NIVOPOST-OP trial, led by Yungang Tao of Gustave Roussy Cancer Center, was published in The Lancet, delivering the first…
Connecting Medical Expertise through Media